PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Friday, September 18, 2020 at 8:00 a.m. ET and host investor meetings.
To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.comMedia Contact:
Jeffrey Nau PhD, MMS
President and Chief Executive Officer
media@oysterpointrx.com
Bay Street News